Objective: To determine the long-term safety of flunisolide hydrofluoroalkane (HFA) in adults and adolescents with mild-to-moderate asthma. Design and Setting: A 1-year multicentre, randomised, ...
AEROSPAN (flunisolide HFA) 80mcg inhalation aerosol by Acton Pharmaceuticals Acton Pharmaceuticals announced that the FDA has approved the sNDA (Supplemental New Drug Application) for Aerospan ...
Drug discontinued-text Both the 60- and 120-actuation sizes have been discontinued. The Food and Drug Administration (FDA) has posted a discontinuation notice for Aerospan (flunisolide; Meda) ...
Trudell ramps up production of AEROCOUNT ® Dose Indicator in preparation to supply Forest Laboratories, Inc. with commercial volumes to support their CFC to HFA transition on Flunisolide Inhalation ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Acton Pharmaceuticals, Inc. (Acton) announced today that the U.S. Food and Drug Administration (FDA) has approved the sNDA (Supplemental New Drug Application) for ...
Swedish pharmaceutical company Meda bought Massachusetts-based Acton Pharmaceuticals, the maker of a new asthma drug-device combo, for more than $135 million plus milestone payments. The inhaler, ...
Acton has licensed AEROSPAN TM (flunisolide HFA, 80 mcg) Inhalation Aerosol from Forest Laboratories, Inc. which will compete in the $7 billion inhaled steroid market MARLBOROUGH, Mass.--(BUSINESS ...
In this 1-year trial, flunisolide HFA proved to be well tolerated when administered to adolescent or adult patients with mild-to-moderate asthma at a median daily dose of 340µg. The incidence and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results